
Rani Therapeutics Holdings, Inc.
93
Recent developments include clinical progress on RT-114 obesity treatment, FDA acceptance of RaniPill into the Emerging Technology Program, expansion of oral biologics pipeline, management changes, and strategic collaborations.
- Rani Therapeutics is advancing RT-114, a GLP-1/GLP-2 dual agonist oral capsule for obesity, with Phase 1 clinical trial updates expected by year-end 2026 [N3].
- The RaniPill oral delivery platform was accepted into the FDA Emerging Technology Program, highlighting regulatory recognition [N2].
- The company expanded its oral biologics pipeline to include obesity and immunology indications [N4].
- Positive initial Phase 1 data for RT-114 demonstrated strong bioavailability and tolerability; Phase 1b is underway [N5][N6].
- Rani Therapeutics entered an R&D collaboration with PegBio for obesity and metabolic disease candidates [N7].
- Nicholas Maestas was appointed CFO following the departure of the previous CFO, Svai Sanford [N8].
- The company continues to pursue partnerships and clinical development milestones to advance its oral biologics platform [N1].
Rani Therapeutics Holdings, Inc. focuses on developing oral biologics delivery technology through its proprietary RaniPill capsule platform, which includes the RaniPill GO and RaniPill HC configurations. The technology aims to enable oral administration of a wide range of biologics including antibodies, proteins, peptides, and oligonucleotides, providing a convenient alternative to injections. The company is advancing multiple pipeline candidates targeting obesity and inflammatory diseases, including RT-114 (GLP-1/GLP-2 dual agonist), RT-116 (semaglutide), and RT-105 (adalimumab biosimilar). Rani Therapeutics has collaborations with Chugai Pharmaceutical and Celltrion for development and commercialization of oral biologics. The company has no approved products or commercial revenue and is investing in vertically integrated manufacturing capabilities. Recent clinical trials and preclinical data demonstrate promising bioavailability and tolerability profiles for its oral biologics candidates. The company reported a net loss in Q3 2026 and maintains strong liquidity ratios.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing the RaniPill oral delivery platform for biologics and drugs, aiming to replace injections with oral dosing. The company has multiple pipeline candidates including RT-114 (GLP-1/GLP-2 dual agonist for obesity), RT-116 (semaglutide for obesity), and RT-105 (adalimumab biosimilar for inflammatory diseases). Collaborations include agreements with Chugai Pharmaceutical and Celltrion. The company has no approved products or revenue yet and reported a net loss of $7.73 million for Q3 2026 with strong liquidity ratios as of September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S2][S1]
Rani Therapeutics' proprietary RaniPill platform offers a novel oral delivery method for biologics, potentially transforming treatment paradigms by replacing injections with oral dosing. Positive initial clinical data for RT-114 and promising preclinical results for RT-116 and RT-105 support the platform's versatility and bioavailability. Collaborations with Chugai Pharmaceutical and Celltrion provide strategic partnerships and milestone-based funding, enhancing development resources. The company's vertically integrated manufacturing approach may enable rapid innovation and scale-up. Acceptance of RaniPill into the FDA Emerging Technology Program reflects regulatory recognition of the platform's innovation. These factors collectively indicate a strong foundation for advancing oral biologics therapeutics.
Rani Therapeutics is a clinical-stage company with no approved products or commercial revenue, facing the inherent risks of drug development including clinical trial failures, regulatory delays, and high capital requirements. The company's manufacturing investments entail significant fixed costs and capital outlays, which may strain financial resources. Dependence on third-party suppliers and collaborators introduces operational risks. The oral delivery of biologics is a complex scientific challenge, and clinical efficacy and safety must be demonstrated convincingly. Market competition includes established injectable biologics and emerging oral formulations. The company’s ability to build or partner for commercialization remains unproven, adding uncertainty to future revenue generation.
Rani Therapeutics' moat is based on its proprietary oral biologics delivery platform, the RaniPill capsule, which is drug-agnostic and designed to deliver a wide variety of biologics with high bioavailability. The company's vertically integrated manufacturing strategy supports rapid product iteration, quality control, and scalability while protecting intellectual property. Collaborations with established biopharmaceutical companies such as Chugai Pharmaceutical and Celltrion provide access to validated drug substances and potential commercialization pathways. The platform's ability to convert injectable biologics into oral formulations addresses a significant unmet need, potentially differentiating Rani Therapeutics in the biotherapeutics delivery market. However, the company remains clinical-stage with no approved products or commercial revenue, and the moat depends on successful clinical development and regulatory approvals.
• Clinical and Regulatory Risk: The company is in early clinical stages with no approved products; clinical trials may not demonstrate safety or efficacy sufficient for regulatory approval.
• Financial Risk: The company reported net losses and has significant capital expenditures for manufacturing; continued funding is necessary to support development and operations.
• Manufacturing and Supply Chain Risk: Reliance on third-party suppliers and single-source components may affect production; manufacturing scale-up involves substantial fixed costs.
• Commercialization Risk: No established commercial infrastructure; success depends on building or partnering for sales, marketing, and distribution.
Business trends: Advancement of oral biologics platform with clinical trials for obesity and immunology candidates, regulatory recognition, and expanding collaborations.
Execution milestones: Completion of Phase 1 trials for RT-114, initiation of Phase 1 for RT-116, and progress on manufacturing scale-up and partnerships.
Key risks: Clinical and regulatory uncertainties, financial sustainability amid ongoing losses and capital investments, manufacturing scale-up challenges, and commercialization execution.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing oral delivery technology for biologics and drugs, aiming to replace painful injections with oral dosing [S1].
- The company’s proprietary technology is the RaniPill capsule platform, which includes two configurations: RaniPill GO (delivers up to 3 mg of drug in microtablet form) and RaniPill HC (high-capacity version delivering up to 200 µL of liquid drug) [S1].
- RaniPill GO has completed three Phase 1 clinical trials; RaniPill HC is in development and has been tested preclinically with multiple therapeutics including antibodies and peptides [S1].
- RT-114 is a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102) for obesity treatment; a Phase 1 clinical trial was initiated in December 2025 in Australia [S1].
- RT-114 showed positive initial Phase 1 data with strong bioavailability and tolerability; Phase 1b is underway [N5][N6].
- RT-116 is a RaniPill HC capsule containing semaglutide for obesity; preclinical data demonstrated comparable bioavailability and pharmacodynamics to subcutaneous injection; a Phase 1 clinical trial is planned [S1].
- RT-105 is a RaniPill capsule containing an adalimumab biosimilar for inflammatory conditions; preclinical and endoscopic human studies showed comparable pharmacokinetics to subcutaneous administration [S1].
- The company has a collaboration and license agreement with Chugai Pharmaceutical for an oral hemophilia product using RaniPill HC, with upfront and milestone payments totaling up to $185 million plus royalties [S1].
- Rani Therapeutics has entered into a license and supply agreement with Celltrion for adalimumab biosimilar for RT-105 development and commercialization [S1].
- The company pursues partnerships with biopharmaceutical companies to develop oral versions of their biologics using RaniPill technology [S1].
- Rani Therapeutics has a vertically integrated manufacturing strategy including in-house design, prototyping, and pilot manufacturing, supplemented by third-party engineering firms; this supports rapid product iteration and scale-up but requires significant capital investment [S1].
- The company has no approved products or commercial revenue yet and has not established a commercial organization; commercialization plans include building infrastructure or partnering [S1].
- Financial snapshot as of September 30, 2026: cash and equivalents $3.62 million, current assets $48.48 million, current liabilities $9.22 million, net loss $7.73 million for the quarter, basic and diluted EPS of -$0.04; liquidity ratios include a current ratio of 5.26 and cash ratio of 11.07 [S2].
- Recent management changes include appointment of Nicholas Maestas as CFO in mid-2026 [N8].
- Recent news highlights include FDA acceptance of RaniPill into Emerging Technology Program, ongoing clinical updates on RT-114, expansion of oral biologics pipeline into obesity and immunology, and R&D collaborations [N1][N2][N3][N4][N7].
Generated 2026-11-09
- S1 | 2026-03-26 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-10-22 | www.nasdaq.com | Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances | https://www.nasdaq.com/articles/rani-therapeutics-eyes-2027-obesity-data-oral-biologics-platform-advances
- N2 | 2026-10-05 | www.nasdaq.com | Rani Therapeutics' RaniPill Accepted Into FDA Emerging Technology Program | https://www.nasdaq.com/articles/rani-therapeutics-ranipill-accepted-fda-emerging-technology-program
- N3 | 2026-08-27 | www.nasdaq.com | Rani Therapeutics Reports Q2 Update; RT-114 Expansion Data Expected By Year-End | https://www.nasdaq.com/articles/rani-therapeutics-reports-q2-update-rt-114-expansion-data-expected-year-end
- N4 | 2026-08-16 | www.nasdaq.com | Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline | https://www.nasdaq.com/articles/rani-therapeutics-expands-oral-biologics-push-obesity-immunology-pipeline
- N5 | 2026-07-15 | www.nasdaq.com | Rani's RT-114 Oral Capsule Shows Strong Bioavailability In Phase 1a Study; Phase 1b Underway | https://www.nasdaq.com/articles/ranis-rt-114-oral-capsule-shows-strong-bioavailability-phase-1a-study-phase-1b-underway
- N6 | 2026-07-15 | www.nasdaq.com | Rani Therapeutics Reports Positive Initial Phase 1 Data For RT-114 | https://www.nasdaq.com/articles/rani-therapeutics-reports-positive-initial-phase-1-data-rt-114
- N7 | 2026-07-10 | www.nasdaq.com | Rani Therapeutics, PegBio Ink R&D Deal For Obesity, Metabolic Disease Candidates | https://www.nasdaq.com/articles/rani-therapeutics-pegbio-ink-rd-deal-obesity-metabolic-disease-candidates
- N8 | 2026-06-30 | www.nasdaq.com | Rani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure | https://www.nasdaq.com/articles/rani-therapeutics-appoints-nicholas-maestas-cfo-following-sanford-departure
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


